1. Market Research
  2. > Pharmaceutical Market Trends

Vital Signs - Healthcare News - The Analyst's Perspective - June 2014

  • July 2014
  • 8 pages
  • Frost & Sullivan
Report ID: 2231903

Summary

Table of Contents

This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogen's Eloctate, Qiagen's acquisition of Primera Dx, Roche's acquisition of Genia Technologies, Cue's at-home connected lab test, and the Credihealth Teen Clinic.

LIFE SCIENCES
US FDA Approves Biogen’s Hemophilia A Drug Eloctate
Source: Reuters, June 6, 2014

The US Food and Drug Administration (FDA) announced on Friday, June 6, 2014, that it approved Biogen Idec Inc’s
long-lasting hemophilia A drug, Eloctate, adding it to the company’s portfolio of drugs for non-malignant blood
disorders. Eloctate is the first recombinant clotting factor VIII therapy with prolonged circulation in the body,
which eliminates at least one dosing every week for prophylactic use in both children and adults.
The Analyst’s Perspective by Steven Atkinson, Senior Industry Analyst,
Life Sciences, North America

Biogen’s product line continues to grow, especially in the blood disorder area. Eloctate is the second hemophilia
drug approved by the FDA in the past three months, beating the likes of Novo Nordisk and Baxter to market.
Alprolix for hemophilia A was approved in March 2014. These two FDA approvals are the results of Biogen’s
fruitful collaboration with Sobi (Swedish Orphan Biovitrum).

Eloctate was used as a prophylactic in a pediatric study; kids experienced a median annual bleeding rate of 2.0.
Close to half of the subjects had no bleeding episodes to report, and 96% of the children who did experience an
episode said their bleeding was controlled after one or two doses.

Hemophilia A and B combined market population is more than 160, 000 worldwide, with a total combined market
revenue of $7 billion annually. Eloctate and Alprolix are estimated to have combined revenues of over $1.5 billion
by 2019. As an analyst, I would deem this collaboration to be a fairly successful deal if those estimates are met.
With the addition of these recent approvals to Biogen’s current portfolio of multiple sclerosis drugs, Avonex,
Tecfidera and Tysabri, Biogen can possibly tout two blockbuster drugs in the coming years.

Qiagen Buys Primera Dx and Expands its Companion Diagnostics Portfolio
Source: Genomeweb, June 5, 2014
Qiagen, a global giant in the molecular diagnostics segment, recently announced that it acquired PrimeraDx, a
molecular diagnostics start-up in the Boston area. PrimeraDx is primarily known for its flagship product, Modaplex
(also known as the ICEPlex), a multi-analytic and multi-modal testing system. Modaplex is the first of its kind to
use multiple assays for a single sample. It enables the analysis of multiple biomarkers in a single reaction.
The Analyst’s Perspective by Aishwarya Vivekanandan, Industry Analysts,

Life Sciences, North America
Molecular diagnostics is the fastest growing segment in the overall IVD market. The double-digit growth is
primarily contributed by the expanding companion diagnostics market. Large pharmaceutical companies have long
since moved away from the one-size-fits-all model in drug development, realizing the importance of diagnostics
in personalized therapy. Many of these pharmaceutical companies incorporate and partner with global majors
like Qiagen to monitor their developed drugs to encourage personalized medication with patients. This is one of
the underlying reasons that led to the acquisition of PrimeraDx by Qiagen. There were a few other compelling
reasons why Qiagen made the strategic move of acquiring PrimeraDx:

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers
2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 Europe Immunodiagnostics Market: Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 Europe Immunodiagnostics Market: Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 37500
  • Industry report
  • February 2017
  • by Venture Planning Group

This new 31-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test. This report provides a granular strategic analysis of over 100 clinical chemistry, ...


Download Unlimited Documents from Trusted Public Sources

Hormone and Therapy Market in Pakistan and the US

  • May 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Antipsychotic Market and Psychotic Disorder Statistics in Europe

  • May 2017
    2 pages
  • Antipsychotic  

    Therapy  

    Psychotic Disor...  

  • Europe  

    World  

    Hungary  

View report >

Pharmaceutical Markets in the US

  • May 2017
    8 pages
  • Pharmaceutical  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.